The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.

Inclusion Criteria:

• Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status.
• HR+ will be defined as ER and/or PR ≥ 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO / CAP Guidelines27. Triple negative will be classified as ER and PR <10% and HER2-.
• Node positive HER2+ and triple negative breast cancer (ypN+) following receipt of neoadjuvant chemotherapy. HR+/HER2- patients should have ypN2 or ypN3 disease following receipt of neoadjuvant chemotherapy and surgery.
• Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen. To include HER2 directed therapy for HER2+ patients.
• Age ≥ 18.
• Life expectancy ≥ 6 months.
• Eastern Cooperative Oncology Group performance status 0 to 2.
• Patients must be able to understand and the willingness to sign an informed consent for study procedures.
• Ability to understand and stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria:

• Prior diagnosis of systemic metastases.
• Patients with prior history of non-breast cancer malignancies should have NED ≥ 2 years excluding adequately treated non-melanoma skin cancer, in situ cancer of the cervix or bladder.
• Contraindication towards CT IV contrast.
• Chronic kidney disease stage IV or V or end stage renal disease (CrCl <30 ml/min).